SCHEMBL1269712

SCHEMBL1269712

Cc1cc(S(=O)(=O)Nc2cc(C)c(Sc3ccc(S(=O)(=O)N4CCCCC4)cc3)cn2)c(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ POLB P06746 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ THRB P10828 1/20 0.38
▸ FKBP1A P62942 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268840 0.89 KDM4E (0.43) MAPK1L3MBTL1ALDH1A1KMT2AKDM4E
SCHEMBL1269747 0.86 ALDH1A1 (0.42) L3MBTL1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL1268777 0.85 L3MBTL1 (0.41) MAPK1L3MBTL1ALDH1A1KMT2ALMNA
SCHEMBL1269787 0.84 ALDH1A1 (0.40) MAPK1L3MBTL1ALDH1A1KMT2AKDM4E
SCHEMBL1269038 0.83 ALDH1A1 (0.42) MAPK1L3MBTL1ALDH1A1KMT2AKDM4E
SCHEMBL1268782 0.81 MAPK1 (0.43) MAPK1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL1269954 0.79 ALDH1A1 (0.42) MAPK1L3MBTL1ALDH1A1KMT2ALMNA
SCHEMBL1268492 0.78 GAA (0.45) L3MBTL1ALDH1A1LMNAGAAPOLB
SCHEMBL1269613 0.78 ALDH1A1 (0.41) MAPK1L3MBTL1ALDH1A1KMT2AKDM4E
SCHEMBL1268887 0.77 ALDH1A1 (0.46) ALDH1A1KMT2AKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MAPK1 4159/4885L3MBTL1 3486/4885ALDH1A1 2237/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MAPK1 4159/4885L3MBTL1 3486/4885ALDH1A1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback